Increase the possibility of early detection! You can learn about the risk of liver disease through a blood test.
The "HepaSign Liver Disease Risk Test" is a blood test that checks the degree of inflammation in the liver. It evaluates the risk of liver disease in three stages based on the measurement of CK-18F in the blood. By understanding your current liver disease risk, you can identify appropriate measures such as lifestyle improvements and undergoing secondary examinations. Taking early action can lead to early detection and improvement of liver function. 【Key Points】 - Risk check at an early stage before liver fibrosis or cirrhosis occurs. - Measures substances produced during the apoptosis process of liver cells, increasing the possibility of early detection of inflammation. - The test can be conducted quickly with just a blood sample. - No dietary restrictions are required. *For more details, please download the PDF or feel free to contact us.*
Inquire About This Product
basic information
【Recommended for those who apply to any of the following】 ■ Those who drink alcohol frequently ■ Those who often eat high-calorie foods ■ Those with high AST/ALT, blood sugar, blood pressure, or lipids ■ Those with a history of diabetes diagnosis ■ Those who have been told they have fatty liver ■ Those who do not drink alcohol and are not concerned about their liver ■ Those with factors of metabolic syndrome such as obesity ■ Those who want to know the risks leading to liver cancer *For more details, please download the PDF or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please download the PDF or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Our company provides services for disease prevention (Protokey testing) and treatment (receptor-targeted drugs) based on human peptide research. "Protokey testing" is an examination that uses blood bio-marker peptides discovered through our proprietary BLOTCHIP-MS method to assess the risk of various diseases. We conduct biomarker exploration research in collaboration with many universities in Japan and analyze a variety of diseases. Additionally, we offer contract services such as "peptide marker exploration," which involves searching for peptides that could serve as new biomarkers.